Vortioxetine A new option for depression ā MM1604
Vortioxetine has been approved for treatment of adults with major depressiveĀ disorder. It adds to the repertoire of antidepressants available for individualisingĀ treatment and may have particular benefits for patients with cognitiveĀ impairment associated with depression.
In vitro studies indicate that it is an inhibitor of serotonin reuptake and actsĀ as an agonist at the serotonin 5-HT1A receptor, partial agonist at the 5-HT1BĀ receptor and antagonist at the 5-HT1D, 5-HT3 and 5-HT7 receptors.
In adults, the usual starting dose of vortioxetine is 10mg once daily, taken withĀ or without food at any time of day.
Modern Medicine ā AprilĀ 2016
